Here's How You Could Become $26,500 Richer
By Accepting This Offer...

From: Marc Lichtenfeld
Director of Research, Access Research Group

Dear Reader,

On October 15th I’m going to “buy” you 250 shares...
 
Of an amazing little company I’ve been researching for over five months.

One that I believe could turn every $1,000 invested into $26,500 by the end of the year.

So why am I doing this?

In short, there’s a tiny market niche handing out huge gains right now, but most people will never experience how profitable it is.

Considering a small group of people just used it to book gains of 93%... 129%... and even 2,650%...

I’d expect people to flock in droves to get in. 

But that’s not the case.

As you’re about to see, 99% of people don’t have the guts to invest in it.

Bottom line: If you decide to take me up on this offer... I’ll send you a $1,000 check on October 1st. Then you can use the money to buy 250 shares of my October 15th recommendation, if you choose.

I’ll give you the money to buy my next pick - which could make you as much as $26,500 - and you won’t have to spend a dime. And then you sit back and watch me prove my point, as the stock soars higher shortly after.

It’s a simple proposition, really. But there’s a catch: If you’re interested, you need to move fast. This offer won’t last long.

Crazy? Maybe, but it won’t sound nearly so crazy once you understand why I’m doing this.

Here’s the story...

Why I'm Doing Something This Crazy

It started on January 27th...

That’s when my editor sent an email to over 72,000 people regarding details on an “any moment” announcement that I believed would send a $4 stock soaring in a matter of days.

Here’s the exact note he sent:

Within days of sending this letter (I didn’t include the entire report - it’s over 16 pages), the announcement I was expecting hit.

By February 17th the stock soared 129% from $3.11 to $7.14.

Readers who got in quickly had the opportunity to more than double their money... quickly turning $500 into $1,145... $1,000 into $2,290... or $10,000 into $22,900.

That’s how fast the profits can come for those who follow my recommendations.  

So how many of those 72,000 readers would you guess got in on this $1 opportunity? Maybe half? Nope. How about 10%? Not even close.

Take a look at the printout my I.T. guy sent me. It shows the number of orders and the exact dollar amount:

That’s right: Just 209 of the people who received this email got onboard. That’s less than 3/1000th of a percent! (.0029% to be exact)!

It blew me away that less than 3 of every 1,000 people responded.

It’s not like I was charging them an arm and a leg. Price couldn’t have been the issue. So I guess most people are satisfied with measly returns from blue chips and run of the mill stocks you hear about on CNBC.

That or they’re just too chicken to invest where the real money is being made.

Of course, this upset me. I swore right then that I’d never let so many everyday wealth builders miss out on a slam-dunk opportunity like this again.

Can you blame me for being shocked?

I offered to let readers try my research for an entire month for just one dollar – that’s a $500 value. (Heck, hedge funds have paid $30,000 for access to my research).

Yet they didn’t think it was worth it? Are people really that scared of success? 

Of course, not all are so timid. Here’s what a few of the “brave” had to say... the elite few who followed my recommendation…

If you're one of the few with the "guts" to try a more profitable kind of investing... then I'd like to send you a check to buy shares of my next pick.

It's a "ready to soar" stock that could pop within days of my October 15th recommendation... and it could put an extra $26,500 in your pocket by the end of the year.

That's why I'm making you an offer no investment "guru" has ever made. 

An Offer No Sane Person Can Refuse

Call me crazy...

The Man Behind This Crazy Offer Hi, my name is Marc Lichtenfeld. I made a successful living for over 14 years researching under-the-radar companies working on important innovations as a Senior Analyst at a contrarian Wall Street research firm. I'm talking about small, innovative companies, leading the "next wave" in biotech, healthcare and technology. ...Ones you can't readily find information on. ...Ones you can't learn about from Wall Street or from the media. ...The kinds of small-cap opportunities (companies having less than $1 billion market caps) that are normally to be avoided... However, with a seasoned analyst on your side who knows the markets inside and out… This is where the biggest, wildest, life-changing gains are made time and again. But the only way to find companies - that can have a profound impact on your wealth - without getting burned is by doing extensive roll-up-your-sleeves research and having a long list of industry contacts at your side. And that's where I come in... and why I'm confident my October 15th recommendation I'm writing you about today could hand you $26,500 for every $1,000 invested. Read on for full details so you can get a $1,000 check from me so you can buy 250 shares of my next pick.

But if it means sending you $1,000 to buy up to 250 shares out of my own pocket...

Then that's what I'm prepared to do.

You see, the stocks in the niche I'll tell you about in a moment are a little different. They're not something you'll likely hear about on CNBC or read about in the Journal.

And if the type of investing you're about to discover isn't for you, I'll understand.

But I have reason to believe you're one of the 1% who will "get it"...

That's why I'd like to give you a look inside the strategy I've developed to exploit a profitable biotech sub-niche consisting of just 230 stocks... and then I'll show you where you can sign up so I can send you $1,000 that could quickly make you $26,500 richer.

This is the financial impact my research service called Access can have on your life.  

And you'll have risked zero dollars on this trade because I'm giving you the money to buy the shares of my October 15th recommendation.

While some people are too timid to invest in this small sub-niche, I've found it's the most profitable area of the markets…...

Here's another example...

A Sample Of What
You'll Get

BioMarin (NASDAQ: BMRN) is a classic example of the opportunities I'd like to soon start showing you.

The company had a promising drug in Phase III trials that treated a medical condition called Phenylketonuria (PKU) - a disorder characterized by increased amounts of the amino acid phenylalanine in the bloodstream of infants that can lead to mental disabilities.

Wall Street ignored the company, maybe because few analysts could pronounce the condition, but more likely because it's a rare disease that doesn't get as much media attention and research dollars as widespread diseases like cancer and diabetes.

But my research - and my contacts in the medical field - confirmed this was an important development... the first and only of its kind. What's more, no other drug company had anything similar in the pipeline, which meant when and if the drug gained FDA approval, there would be no competition whatsoever.

More research confirmed the drug was being "fast-tracked" - which means the FDA will speed up the approval process because of the urgent medical need. It was just a matter of months before there was a very high likelihood that the drug would gain approval.

So I put out a recommendation. Here it is: 

A few weeks later, news of the drug hit Wall Street. BioMarin soared and hit our target price of $40 within 6 months.

102% to 2,650% Gains in Under 6 Months

Those who followed the recommendation had an opportunity to walk away with solid money-doubling gains in just five months - like John S., from Houston, TX:

"Great call on this stock! Without your recommendation I never would have even heard of this company. I am up 101.75% and will sell half of my position on Monday. Please continue to bring these types of picks! I realize that there is always uncertainty around the FDA approval process, but you nailed this one. Again, great job!"

Some did better buying the options, given my suggestion the stock would move quickly once Phase III trial results were announced.

That's when the letters really started pouring in:

"Last Friday, I sold all 10 BioMarin contracts for $11 each!! Turning my $400 investment into $11,000 - a gain of $10.60 per contract [that's a 2,650% gain]!! (Not including the $40 'round trip' for brokerage). I sure am going to have a great Christmas!" -Joshua R., Australia

"Great call! I bought the Jan 09 $17.50 calls at $5.30 and sold them today at $19.50. Sweet! Keep up the good work." -Jason M., Easley, SC

"I decided to go the options route and purchased January calls at $2.10. Sold 40 percent for a 57.1% locked in gain. Today I sold the balance for an additional 447.6% gain. Total gain: about 505%." -Doug G., Chester, PA

The Risk & The Reward

If you say to yourself: "This might not be for me. I'm going to stick with the safe and steady stocks I know. Who's to say this Lichtenfeld guy really isn't crazy anyway?"

Well then, I'll understand.

After all, nobody can be absolutely sure about any company's prospects, especially little healthcare and biotech innovators like the ones I uncover.

It's possible that the medical devices, drugs or procedures never make it to market.

After all, the FDA has squelched the dreams of many hopeful innovators and investors before.

It could happen again.

But here's what I want you to know: Over the last 14 years I've discovered secrets to uncovering companies that successfully get through the trial process with over 90% accuracy.

You see, the companies I identify are small-caps and start-up companies with $50-$500 million dollar market caps that are in what we like to call "the gathering period" - where influential investors, insiders, and sector specialists are accumulating substantial positions ahead of breakthrough news and/or product announcements.

I've made a very successful living over the past 14 years researching these small-cap companies working on important innovations - both as a senior analyst at Wall Street's most contrarian research firm, hired by the biggest investment and hedge funds in the world… and most recently as the Director of Research for my own institutional-style advisory service called Access.

Most People Will Never Experience
Anything Like This

If you're not familiar with it, Access provides you with the type of research and insight into up-and-coming companies you can't possibly get from any newsletter, alert service, or investment "guru"... and certainly not from The Wall Street Journal.

Over the years you start to learn the little "telltale" signs that a company's innovations are difference makers. You see it in how willing they are to answer the hard questions you ask them.

You see it in the way the company goes about its business, looking to the long term - even if today's tough decisions impact the share prices in the short term.

You see it in the way company executives, directors, and even salaried employees quietly and consistently buy up company stock.

And perhaps most telling is the passion in their voices when executives talk about their company and products.

I've spoken with many CEOs, CFOs and doctors over the years and I can honestly tell you that when these people are more interested in the life-saving aspect of their devices and drugs than they are about getting rich from it, investors following their lead stand to make a hefty profit. 

Only when all the tangibles and intangibles are in place - will I recommend a company to Access Research subscribers.

The Best Research. Period.

As you may have guessed this is serious research.

I don't just scan the markets or read over financials.

Every upstart opportunity I consider is put through our highly successful and very grueling "F.I.R.S.T." analysis.

Right off the bat I take a hard look at the company's financials to determine if there's adequate funding, if there's a large enough market for the products and what the future revenues will be.

After all, a company can develop a wonderful life-saving drug or product - but if there's little market for the product, how lucrative could it be?

So three important factors I examine very carefully are 1) size and scope of the market...
2) the "uniqueness" of the product... and 3) the kind of market share the product can expect to have.

Once the financials pass muster, we begin the long and thorough interview process.

I talk to the players.

I travel to the company.

I interview the salespeople, the CEOs, the production people, company executives and even workers on the floor.

I interview executives at competing companies.

I talk to potential or current customers.

I talk to industry and sector experts.

I talk to our Wall Street contacts - boardroom people, CEOs, fund managers, floor traders - just to get a sense for the market.

Next comes months and months of hardcore research - where I spend thousands of hours pouring over scientific papers, medical journals, study reports, industry statistics, commentary and blogs with my team of researchers - anything that will help us better understand the product, the market, and the potential for the product.

The Single Most Important Factor Virtually
Everyone Else Overlooks

Much of our research effort goes into determining the safety factor of the product.
Why? Because this is where over 90% of the new and promising medical products get tripped up in the FDA process.

Many investors have been burned by companies whose drugs or products clearly work in all phases of testing - but sometimes one small side effect can be enough for a gun shy FDA to withhold its approval.

The final piece of the F.I.R.S.T analysis puzzle is timing.

If you're a shareholder, you want in on the ground floor - but you don't want your money tied up in a stock that's not about to move for years.

That's why as part of our research, we look for a catalyst… a series of upcoming events with the potential to move the stock: preliminary data, financing, potential approvals and so on.

Once everything adds up, we put together a private conference call where we invite an impartial industry expert to join us in putting the hard questions to management.

And we invite you, and your fellow Access subscribers, to listen in.

Very serious stuff.

In fact, we may do six months of in-depth, exhaustive research on a single company... only to discover it doesn't meet our high standards for an Access recommendation. (We'll tell you about those too - just in case you see them "written up" elsewhere - as we have seen - and you're tempted to buy).

A Unique Opportunity For You to Profit From the Research Wall Street's Top Firms Pay $30,000 To Get

The research you'll get with Access is unlike anything you've likely seen.

Instead of preparing it for the world's most elite money managers, like I used to do, my team and I do it for you.

I'll give you a snapshot of the companies in our model portfolio in a moment. I'll also tell you how you can try Access for 30 days without a monetary risk to you through this special offer.

And, of course, I'll show you how to get up to 250 shares of my next recommendation on October 15th at no cost.

How's that for an offer? Not only will I recommend the pick, but I'll also give you the money to buy it.

But first, if you're already investing in the markets, I have a couple of important questions to ask you...

How satisfied are you with your current stock portfolio?

Are you satisfied with the returns you're getting?

If not, you're not alone.

If you said yes, allow me to pose another question...

How satisfied are you knowing there is - and always has been - a very small circle of insiders who get privileged information long before you ever see it?

I'm not talking "buy Microsoft because word on the street is they're going to beat earnings estimates."

I'm talking about a situation where a fund trader or industry insider - someone with privileged access - calls a friend and says, "Hey, you might want to take a look at this. A lot of people I know close to this situation are buying this stock now."

Here's why...

Is it fair? Who's to say?

The insiders I'm talking about - people I know and talk to everyday - have spent their entire careers getting to this "inner circle." They're smart. They're experts in their respective fields. They're insiders at the actual companies.

And they know how to make (and keep) friends in the right places. So from that perspective, yes - they've earned it.

But does that mean you shouldn't take advantage of their knowledge and expertise if you had an opportunity to do so?

Absolutely not.

Again, this is the kind of roll-up-your-sleeves research and information that can have a profound effect on your wealth.

Needless to say, I want you to get in on our next opportunity... and I'd love to send you $1,000 to get started.

Of course, it would be great to see you better than double or triple your money overnight. What better way after all, to make up for some of the losses the market's handed investors lately?

But more importantly, I want you to see the kind of extraordinary research we do here... and how we're able to unearth the kind of companies that can have a profound impact on your immediate wealth.

Like the ones already in our model portfolio...

Boost Your Gains Right Out Of The Gate

The minute you become an Access subscriber you're entitled to details and reports on eight very exciting (and timely) situations currently in our portfolio.

In fact, each of these companies is performing quite well, even in this difficult market.

Despite the fact that the catalysts we expect to drive these shares higher are still a few weeks away...

Cumulatively, we're trouncing the S&P 500 by 40% on ALL of our open positions.

Insiders are very active in a number of them as they line up their stakes in this, the "gathering" period for these stocks.

Here's a taste of what you'll get:

164% potential gains on this stem cell play...

A non-embryonic stem cell company with existing products in the marketplace. Physicians who use their products are already expanding their use beyond what they have been approved for - opening the door to dozens of new uses. Many clinical trials are currently underway to gain approval for expanded use. If those are strong, investors will recognize this therapy is for real. Projected Gains: 164%

$100 Million to fight bio-terror...

A biotechnology company that's expected to land a $100 million contract from the U.S. government any day now for a product that combats bio-terror and viruses. The firm got a huge boost when its drug was successfully used on an emergency basis to help save the life of a toddler who contracted a small pox related illness. Once the deal is sealed, this $7.00 stock could more than double by the end of the year. Projected Gains: 165%

369% potential gains on this medical device innovator...

A medical device maker that's a strong acquisition candidate. It's developed a number of innovative new products - among them a product for the female market with the potential for $500 million in new sales if it captures the same 5% of the market it currently has for its men's version of the product. Projected Gains: 369%

Potential gains of 65% on this under-the-radar pioneer...

Wall Street has missed the boat with this medical device company that's dominating its competition. It's so far ahead that it could soon have a virtual monopoly. Its success comes from a major breakthrough in its respected field, the first significant development to hit in 40 years. Plus, the medical director of this company is the pioneer of a well-known cardiac procedure. Projected Gains: 65%

A cash-rich California-based biotech dominating in China...

A little biotech that's flying under-the-radar, because it's marketing its main drug in China. And it already has drugs in its pipeline that should be approved in China by 2011. Plus, this company is sitting on a pile of cash and has NO debt. But it gets better: It also has a drug for swine flu. If another pandemic (anywhere in the world) breaks out, its drug is likely to be used. Projected Gains: 109%  

Of course you'll get full reports with all the details on each of these companies - and three more - the minute you join Access.

Any one of the 8 companies you'll learn about could have a profound impact on your wealth. These companies are truly in the early "gathering" stages, each with important events on the near-term horizon that could drive these stocks much higher, very quickly.

What's more, they fit the Access selection criteria perfectly: Little-known companies flying well under the radar, with highly promising, groundbreaking and innovative products just months away from hitting the market.

Why You May Not Be Right for this Service

Still, I need you to carefully consider whether Access is right for you.

There are basic investing skills you should know to get the most out of this advisory service... like how to place limit orders and where you instruct your broker to buy or sell at specific prices.

And although this is a 'buy-and-hold' strategy... our positions can pop at any time. It is best to be an 'active' investor.

Since even the smallest bit of news can move our positions, you really need to have the ability to check your email on a regular basis.

If you're not there to get the recommendations or updates - and to place your limit buy and sell orders - you could miss out on potentially thousands of dollars in fast gains.

Then, of course, there's the price it will cost to join this research service.

Understand this is not an amateur service.

Access uses serious, professional research, which I've spent years of my life and hundreds of thousands of dollars on - the caliber of research professional traders and institutions rely on to move millions of dollars through the markets each and every day.

And the price reflects that.

The cost to join Access is $6,000 a year. That's a bargain when you consider institutions and hedge funds were paying me upwards of $30,000 a pop for my research.

I'm very confident in the quality research we provide here at Access. Institutional money managers tell me the research I publish is as good or better than anything they've seen - even from some of the most prestigious firms on Wall Street.

When I started Access, my goal was to give typical wealth builders like you access to the kind of research the big guys are privy to, so you can have the same "edge" on the market they do...

That's why we spend hundreds of thousands of dollars every year traveling to companies' headquarters, wining and dining industry contacts, trying to squeeze out, by any legal means, close-to-the-bone information that will lead us to hidden opportunities with enormous potential.

At the same time, I know this is a very difficult time for all investors. Given how tight money is these days - and how unpredictable the market is right now - I understand the decision to spend $6,000 on a research service is a lot of money to say the least.

But I'm so convinced that this research could reward you so profoundly - starting just weeks from now with the shares I'm going to "buy" you - that I'm "putting my money where my mouth is"...

Act Now And Get Over HALF OFF!

Through a special arrangement for new subscribers, you can subscribe to Access today for just $2,795 per year.

That's over $3,200 off the published price - a 54% savings.

This could be your last chance to get in at this price. Under the terms we've arranged, this special price can be closed to new subscribers at any time.

But know this: Once you're in at the special $2,795 price, you'll never be asked to renew your subscription at the $6,000 amount. You'll essentially 'lock in' this special annual renewal rate for life.

Plus, you can check Access out for 30 days risk-free...

Here's how it works: If you decide for any reason this style of research isn't for you, just let us know and we'll be happy to give you a prompt, full, refund at any time during the first 30 days of your subscription.

I think you'll agree this is a very fair offer.

We're confident Access will produce enough substantial gains to make you very happy... and pay for your subscription many times over.

However, there's something I need to make sure you're clear on, and I'm sorry if this seems direct, but if you're expecting 20, 30, or 50 recommendations a year, you may be disappointed.

Access is designed specifically to provide you with 6 - 8 extremely well-researched picks a year - on opportunities that can offer you extraordinary gains - in just months.

The thrill of a FDA approval coming over the wire and giving us faster-than-anticipated gains is exhilarating. Just like a few months ago when a little company's announcement sent the stock I recommended soaring 129% in just 21 days.

That's why I'm going to give you every reason to get in now, and send your $1,000 check to buy shares of my October 15th recommendation... that could easily double by December 31st.

But here's the thing...

This Invitation is Open for a Limited Time

As I mentioned before - this invitation will remain open for a limited time. That's why I urge you to act today.

So you can get shares of my next recommendation at no cost to you.

The moment I feel we've got all the subscribers my recommendation can comfortably handle, I will close the door to new subscribers. Possibly forever.

If we hear from you today, you'll virtually guarantee securing your place for the special offer we've arranged.

Let's go over this just one more time...

How This Offer Works

So here's how it works once more.

By joining today you'll gain instant access to all of our current research... and I'm slashing the price in half so you're saving $3,200.

On October 1st I'll mail you a $1,000 check.

You then decide if you'd like to pocket the money or buy shares of my October 15th recommendation.

Of course, if you cancel in the first 30 days, before Sept 29th, I won't be able to mail you a $1,000 check... and you'll miss out on the opportunity to turn that $1,000 into $26,500.
It's really as simple as that.

Time is of the Essence

By acting today...

You'll get immediate access to our current portfolio... a $3,200 savings off the regular price... and I’ll send you a $1,000 check on October 1st.

I urge you to hurry. This offer disappears forever promptly at midnight, Saturday August 29th.

To sign up for Access - and get your special rate - you must order online. So simply now to get onboard.

I look forward to having you onboard.

Sincerely,

Marc Lichtenfeld
Director of Research
Access Research Group

P.S. This is a one-time offer. That means I must hear from you right away so you can get on the list to receive a $1,000 check that you can use to buy 250 shares of my next pick... and so you can save $3,200 off the regular price - a 54% savings.  

Please note: 250 shares is an estimate of how many shares the check for $1,000 - that I'm sending in US Funds ONLY - will buy. Of course, if the stock price of my next recommendation moves above $4.00, the number of shares will decrease.